Clinical Trial Update: Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing 2 vs 4 cycles of neoadjuvant CAPOX for low/intermediate risk II/III rectal cancer; current status is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: West China Hospital | Conditions: Rectal Cancer, Neoadjuvant Chemotherapy | Phase 3 | Status: ACTIVE_NOT_RECRUITING